董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Guy C. Jackson | 男 | Independent Director | 73 | 19.00万 | 未持股 | 2015-07-28 |
| Joseph E. Laptewicz, Jr. | 男 | Independent Director | 66 | 18.25万 | 未持股 | 2015-07-28 |
| Daniel J. Moore | 男 | Director, Chief Executive Officer & President | 54 | 442.33万 | 未持股 | 2015-07-28 |
| Hugh M. Morrison | 男 | Independent Chairman | 68 | 25.10万 | 未持股 | 2015-07-28 |
| Alfred J. Novak | 男 | Independent Director | 67 | 18.00万 | 未持股 | 2015-07-28 |
| Arthur L. Rosenthal | 男 | Independent Director | 68 | 19.00万 | 未持股 | 2015-07-28 |
| Jon T. Tremmel | 男 | Independent Director | 69 | 17.25万 | 未持股 | 2015-07-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rohan H. Hoare | 男 | Senior Vice President & Chief Operating Officer | 50 | 148.08万 | 未持股 | 2015-07-28 |
| Daniel J. Moore | 男 | Director, Chief Executive Officer & President | 54 | 442.33万 | 未持股 | 2015-07-28 |
| Gregory H. Browne | 男 | Senior Vice President, Finance & Chief Financial Officer | 62 | 96.08万 | 未持股 | 2015-07-28 |
| David S. Wise | 男 | Senior Vice President, Chief Administrative Officer & Secretary | 60 | 94.15万 | 未持股 | 2015-07-28 |
| Darren W. Alch | 男 | Vice President, General Counsel & Assistant Secretary | 49 | 66.77万 | 未持股 | 2015-07-28 |
董事简历
中英对照 | 中文 | 英文- Guy C. Jackson
-
Guy C. Jackson, Jackson先生2003年11月以来一直是我们董事会的成员。2003年6月，Jackson 先生从Ernst & Young LLP 律师事务所退休，他在那里工作了35年，也是该律师事务所的创始人之一，其前身是Arthur Young & Company。在他的职业生涯里，他在很多上市公司担任审计合伙人。Jackson 还担任 Cyberonics, Inc.和 Life Time Fitness, Inc. 的审计委员会成员和主席。他是EpiCept Corporation 和Urologix, Inc.的前董事。
Guy C. Jackson,Mr. Jackson has been a member of our Board of Directors since November 2003. In June 2003 Mr. Jackson retired from the accounting firm of Ernst & Young LLP after 35 years with the firm and one of its predecessors, Arthur Young & Company. During his career, he served as the audit partner on a number of public companies. Mr. Jackson also serves as a director and chair of the audit committees of Cyberonics, Inc. and Life Time Fitness, Inc. He is a former director of EpiCept Corporation and Urologix, Inc. - Guy C. Jackson, Jackson先生2003年11月以来一直是我们董事会的成员。2003年6月，Jackson 先生从Ernst & Young LLP 律师事务所退休，他在那里工作了35年，也是该律师事务所的创始人之一，其前身是Arthur Young & Company。在他的职业生涯里，他在很多上市公司担任审计合伙人。Jackson 还担任 Cyberonics, Inc.和 Life Time Fitness, Inc. 的审计委员会成员和主席。他是EpiCept Corporation 和Urologix, Inc.的前董事。
- Guy C. Jackson,Mr. Jackson has been a member of our Board of Directors since November 2003. In June 2003 Mr. Jackson retired from the accounting firm of Ernst & Young LLP after 35 years with the firm and one of its predecessors, Arthur Young & Company. During his career, he served as the audit partner on a number of public companies. Mr. Jackson also serves as a director and chair of the audit committees of Cyberonics, Inc. and Life Time Fitness, Inc. He is a former director of EpiCept Corporation and Urologix, Inc.
- Joseph E. Laptewicz, Jr.
-
Joseph E. Laptewicz, Jr.，2008年9月起担任本公司董事。他于2000年退休，时任业务行政官员，他在医疗器械行业有着丰富的经验。1998-2005，他是Advanced Neuromodulation Systems的董事，这是一个上市公司，从事生产治疗疼痛的植入式神经调节器，于2005年被St. Jude Medical收购。1996-2003，他是AngioDynamics的董事，这是从事制造介入性心脏病产品的上市公司。1994-2000，他担任Empi的总裁、首席执行官；2001-2004，担任该公司董事长，这是著名的用于止痛治疗和物理康复的无创性医疗产品的制造和供应商。1972-1994，他在辉瑞的多个子公司担任了多个愈益重要的职务，辉瑞在当时是一个大型的制药和医疗技术公司，任职包括：1990-1991，担任Schneider USA副总裁、总经理；1991-1994，担任总裁，这是一个全球性的导管、支架以及相关医疗产品制造公司。
Joseph E. Laptewicz, Jr.,Mr. Laptewicz has been a member of our Board since September 2008. Mr. Laptewicz, who retired as a business executive in 2000 has extensive medical device experience. From 1998 to 2005 he served on the board of directors of Advanced Neuromodulation Systems, Inc., a publicly held manufacturer of implantable neuromodulation devices for the treatment of pain acquired by St. Jude Medical, Inc. in 2005. From 1996 to 2003 he served on the board of directors of AngioDynamics, Inc., a publicly held manufacturer of interventional radiology products. From 1994 to 2000 Mr. Laptewicz served as President and CEO, and from 2001 to 2004 as Chairman of the board of directors, of Empi, Inc., a leading manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. From 1972 to 1994 Mr. Laptewicz served in various positions of increasing responsibility for subsidiaries of Pfizer, Inc., at the time, a large pharmaceutical and medical technology company, including Vice President and General Manager from 1990 to 1991 and President from 1991 to 1994 of Schneider USA, Inc., a worldwide manufacturer of catheters, stents, and related medical products. - Joseph E. Laptewicz, Jr.，2008年9月起担任本公司董事。他于2000年退休，时任业务行政官员，他在医疗器械行业有着丰富的经验。1998-2005，他是Advanced Neuromodulation Systems的董事，这是一个上市公司，从事生产治疗疼痛的植入式神经调节器，于2005年被St. Jude Medical收购。1996-2003，他是AngioDynamics的董事，这是从事制造介入性心脏病产品的上市公司。1994-2000，他担任Empi的总裁、首席执行官；2001-2004，担任该公司董事长，这是著名的用于止痛治疗和物理康复的无创性医疗产品的制造和供应商。1972-1994，他在辉瑞的多个子公司担任了多个愈益重要的职务，辉瑞在当时是一个大型的制药和医疗技术公司，任职包括：1990-1991，担任Schneider USA副总裁、总经理；1991-1994，担任总裁，这是一个全球性的导管、支架以及相关医疗产品制造公司。
- Joseph E. Laptewicz, Jr.,Mr. Laptewicz has been a member of our Board since September 2008. Mr. Laptewicz, who retired as a business executive in 2000 has extensive medical device experience. From 1998 to 2005 he served on the board of directors of Advanced Neuromodulation Systems, Inc., a publicly held manufacturer of implantable neuromodulation devices for the treatment of pain acquired by St. Jude Medical, Inc. in 2005. From 1996 to 2003 he served on the board of directors of AngioDynamics, Inc., a publicly held manufacturer of interventional radiology products. From 1994 to 2000 Mr. Laptewicz served as President and CEO, and from 2001 to 2004 as Chairman of the board of directors, of Empi, Inc., a leading manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. From 1972 to 1994 Mr. Laptewicz served in various positions of increasing responsibility for subsidiaries of Pfizer, Inc., at the time, a large pharmaceutical and medical technology company, including Vice President and General Manager from 1990 to 1991 and President from 1991 to 1994 of Schneider USA, Inc., a worldwide manufacturer of catheters, stents, and related medical products.
- Daniel J. Moore
-
Daniel J. Moore，2007年5月被任命为本公司董事，与此同时，他被本公司董事会任命为总裁兼首席执行官。加入本公司前，他任职于 Boston Scientific Corporation（Boston Scientific）， 这是一个多元化的微创医疗产品制造公司；他从1989年以来，在该公司的美国和欧洲业务部门担任过多个销售、营销和高级管理的职务。他在Boston Scientific 的最后职位是国际分销商管理总裁。担任该职之前，他是 Boston Scientific第4大业务部门Inter-Continental的总裁，该部门在全球有1000多名员工，营业额超过7亿美元。他也曾在Boston Scientific 的美国国内和国际性部门担任过高级管理职位。他目前担任美国癫痫基金会、德克萨斯癫痫基金会（前任会长）、德克萨斯州-休斯敦癫痫基金会（前任主席）的董事，也是医疗器械制造商协会的董事长，还是以下机构的董事或咨询委员会成员： BioHouston、Medical Device Innovation Consortium、Weldon School of Biomedical Engineering at Purdue University。他还是两家私营公司的董事：TriVascular，是一家医疗技术公司，为主动脉腔内修复提供器械的解决方案；BrainScope，专注于创伤性脑板伤害的医疗技术公司。由于他在担任Boston Scientific的主管人员时，还是阿根廷分公司的董事，他成为了2011年5月在布宜诺斯艾利斯联邦刑事和惩教事务法院4号法庭提起的刑事诉讼的几名被告之一。该诉讼涉及到与2006年心脏支架销售的公开招标有关的涉嫌欺诈行为。他否认了对指控的欺诈行为的任何知情或罪责，并敦促撤消指控。
Daniel J. Moore was appointed as Chairman of LivaNova's Board of Directors in September 2015. In addition to our Board, Mr.. Moore currently serves on the board of directors of GI Dynamics, Inc. Chairman, BrainScope Company, Inc. (Chairman), a company focused on traumatic brain injury, the BioHouston Executive Committee, Weldon School of Biomedical Engineering Advisory Board, and the Epilepsy Foundation of America. Previously, beginning in 2007 Mr.. Moore was a member of the Board and served as Chief Executive Officer of Cyberonics. Mr.. Moore joined Cyberonics from Boston Scientific, where, since 1989 he held positions in sales, marketing and senior management in the U.S. and in Europe. His last position at Boston Scientific was President, International Distributor Management. Prior to that role, he held the position of President, Inter-Continental, the fourth largest business unit of Boston Scientific, with more than 1000 global employees and revenues exceeding $700 million. Past board positions include: Topera, Inc. (acquired by Abbott Laboratories), TriVascular Technologies, Inc. (acquired by Endologix, Inc.), the Medical Device Manufacturers Association (past-Chairman), Smiling Kids, Inc., the Epilepsy Foundation of Texas (past-Chairman) and the Epilepsy Foundation of Texas-Houston (past President). Mr.. Moore earned an Executive MBA from Boston University and a Bachelor of Arts in Economics from Harvard College. - Daniel J. Moore，2007年5月被任命为本公司董事，与此同时，他被本公司董事会任命为总裁兼首席执行官。加入本公司前，他任职于 Boston Scientific Corporation（Boston Scientific）， 这是一个多元化的微创医疗产品制造公司；他从1989年以来，在该公司的美国和欧洲业务部门担任过多个销售、营销和高级管理的职务。他在Boston Scientific 的最后职位是国际分销商管理总裁。担任该职之前，他是 Boston Scientific第4大业务部门Inter-Continental的总裁，该部门在全球有1000多名员工，营业额超过7亿美元。他也曾在Boston Scientific 的美国国内和国际性部门担任过高级管理职位。他目前担任美国癫痫基金会、德克萨斯癫痫基金会（前任会长）、德克萨斯州-休斯敦癫痫基金会（前任主席）的董事，也是医疗器械制造商协会的董事长，还是以下机构的董事或咨询委员会成员： BioHouston、Medical Device Innovation Consortium、Weldon School of Biomedical Engineering at Purdue University。他还是两家私营公司的董事：TriVascular，是一家医疗技术公司，为主动脉腔内修复提供器械的解决方案；BrainScope，专注于创伤性脑板伤害的医疗技术公司。由于他在担任Boston Scientific的主管人员时，还是阿根廷分公司的董事，他成为了2011年5月在布宜诺斯艾利斯联邦刑事和惩教事务法院4号法庭提起的刑事诉讼的几名被告之一。该诉讼涉及到与2006年心脏支架销售的公开招标有关的涉嫌欺诈行为。他否认了对指控的欺诈行为的任何知情或罪责，并敦促撤消指控。
- Daniel J. Moore was appointed as Chairman of LivaNova's Board of Directors in September 2015. In addition to our Board, Mr.. Moore currently serves on the board of directors of GI Dynamics, Inc. Chairman, BrainScope Company, Inc. (Chairman), a company focused on traumatic brain injury, the BioHouston Executive Committee, Weldon School of Biomedical Engineering Advisory Board, and the Epilepsy Foundation of America. Previously, beginning in 2007 Mr.. Moore was a member of the Board and served as Chief Executive Officer of Cyberonics. Mr.. Moore joined Cyberonics from Boston Scientific, where, since 1989 he held positions in sales, marketing and senior management in the U.S. and in Europe. His last position at Boston Scientific was President, International Distributor Management. Prior to that role, he held the position of President, Inter-Continental, the fourth largest business unit of Boston Scientific, with more than 1000 global employees and revenues exceeding $700 million. Past board positions include: Topera, Inc. (acquired by Abbott Laboratories), TriVascular Technologies, Inc. (acquired by Endologix, Inc.), the Medical Device Manufacturers Association (past-Chairman), Smiling Kids, Inc., the Epilepsy Foundation of Texas (past-Chairman) and the Epilepsy Foundation of Texas-Houston (past President). Mr.. Moore earned an Executive MBA from Boston University and a Bachelor of Arts in Economics from Harvard College.
- Hugh M. Morrison
-
Hugh M. Morrison，2006年11月被任命为本公司董事会成员。从2012年7月至今，他从事独立顾问和投资的工作。从2008年9月至2012年6月，他是投资管理公司Callahan Advisors的总经理。从1983年到2005年12月，他担任Advanced Neuromodulation Systems的董事；从1998年1月至2005年12月，担任该公司董事长，这是一家上市公司，从事先进的植入式神经刺激设备的设计、开发、制造和营销，在2005年被St. Jude Medical收购。从1994年起，他担任医院药品管理上市公司 Owen Healthcare的董事，直到1996年该公司被Cardinal Healthcare收购。此外，他从1984年起担任药品制造和营销公司Dow Hickam Pharmaceuticals的董事，直到1991年该公司被出售给Mylan Laboratories。1996年3月至2006年5月，他担任Pilgrim Cleaners（Pilgrim）及其母公司Clean Acquisition（Clean） 的总裁兼首席执行官；从1998年1月至2006年5月，担任Pilgrim Cleaners及其母公司Clean Acquisition的董事长，这是一个零售干洗公司，经营着超过100间分店。2004年1月，Pilgrim 和Clean 根据美国破产法第11章，在美国破产法院德克萨斯南区休斯顿分院提交了破产保护申请。在他辞职之后，Pilgrim and Clean 根据美国破产法第7章，在美国破产法院德克萨斯南区休斯顿分院提交了破产申请。他是一名注册会计师。
Hugh M. Morrison was appointed to LivaNova’s Board of Directors as a non-executive director in October 2015. Currently, Mr.. Morrison serves on the board of directors of the Texas A&M University, Kingsville Foundation and the Rockport Center for the Arts. From July 2012 to present, Mr.. Morrison has also engaged in independent consulting and investments. Previously, Mr.. Morrison served on the board of directors of Cyberonics since November 2006. From September 2008 through June 2012 he was a Managing Director at Callahan Advisors, LLC, an investment management company. Previously, from 1983 to December 2005 Mr.. Morrison served as a director, and from January 1998 to December 2005 as Chairman of the board of directors, of Advanced Neuromodulation Systems, Inc., a publicly held designer, developer, manufacturer and marketer of advanced implantable neurostimulation devices acquired by St. Jude Medical, Inc. in 2005. Mr.. Morrison served as a director of Owen Healthcare, Inc., a publicly held hospital pharmacy management firm, from 1994 until it was acquired in 1996 by Cardinal Healthcare. In addition, Mr.. Morrison served as a director of Dow Hickam Pharmaceuticals, Inc., a pharmaceutical manufacturer and marketer, from 1984 to 1991 when the company was sold to Mylan Laboratories, Inc. From March 1996 to May 2006 Mr.. Morrison served as President and Chief Executive Officer, and from January 1998 to May 2006 as Chairman of the Board of Directors, of Pilgrim Cleaners, Inc., a retail dry cleaning company operating over 100 stores. Mr.. Morrison earned a BBA in Accounting from Texas A&M University-Kingsville and he is licensed as a Certified Public Accountant. - Hugh M. Morrison，2006年11月被任命为本公司董事会成员。从2012年7月至今，他从事独立顾问和投资的工作。从2008年9月至2012年6月，他是投资管理公司Callahan Advisors的总经理。从1983年到2005年12月，他担任Advanced Neuromodulation Systems的董事；从1998年1月至2005年12月，担任该公司董事长，这是一家上市公司，从事先进的植入式神经刺激设备的设计、开发、制造和营销，在2005年被St. Jude Medical收购。从1994年起，他担任医院药品管理上市公司 Owen Healthcare的董事，直到1996年该公司被Cardinal Healthcare收购。此外，他从1984年起担任药品制造和营销公司Dow Hickam Pharmaceuticals的董事，直到1991年该公司被出售给Mylan Laboratories。1996年3月至2006年5月，他担任Pilgrim Cleaners（Pilgrim）及其母公司Clean Acquisition（Clean） 的总裁兼首席执行官；从1998年1月至2006年5月，担任Pilgrim Cleaners及其母公司Clean Acquisition的董事长，这是一个零售干洗公司，经营着超过100间分店。2004年1月，Pilgrim 和Clean 根据美国破产法第11章，在美国破产法院德克萨斯南区休斯顿分院提交了破产保护申请。在他辞职之后，Pilgrim and Clean 根据美国破产法第7章，在美国破产法院德克萨斯南区休斯顿分院提交了破产申请。他是一名注册会计师。
- Hugh M. Morrison was appointed to LivaNova’s Board of Directors as a non-executive director in October 2015. Currently, Mr.. Morrison serves on the board of directors of the Texas A&M University, Kingsville Foundation and the Rockport Center for the Arts. From July 2012 to present, Mr.. Morrison has also engaged in independent consulting and investments. Previously, Mr.. Morrison served on the board of directors of Cyberonics since November 2006. From September 2008 through June 2012 he was a Managing Director at Callahan Advisors, LLC, an investment management company. Previously, from 1983 to December 2005 Mr.. Morrison served as a director, and from January 1998 to December 2005 as Chairman of the board of directors, of Advanced Neuromodulation Systems, Inc., a publicly held designer, developer, manufacturer and marketer of advanced implantable neurostimulation devices acquired by St. Jude Medical, Inc. in 2005. Mr.. Morrison served as a director of Owen Healthcare, Inc., a publicly held hospital pharmacy management firm, from 1994 until it was acquired in 1996 by Cardinal Healthcare. In addition, Mr.. Morrison served as a director of Dow Hickam Pharmaceuticals, Inc., a pharmaceutical manufacturer and marketer, from 1984 to 1991 when the company was sold to Mylan Laboratories, Inc. From March 1996 to May 2006 Mr.. Morrison served as President and Chief Executive Officer, and from January 1998 to May 2006 as Chairman of the Board of Directors, of Pilgrim Cleaners, Inc., a retail dry cleaning company operating over 100 stores. Mr.. Morrison earned a BBA in Accounting from Texas A&M University-Kingsville and he is licensed as a Certified Public Accountant.
- Alfred J. Novak
-
Alfred J. Novak，2007年1月被任命为本公司董事会成员。1999年9月起，他是OrbusNeich Medical Technology Company的董事会成员，这是一个介入性心脏病方面的私营公司，他在2010年1月当选为董事长兼首席执行官。之前，他曾担任ProRhythm的董事长，该公司致力于通过采用超声波技术治疗心房颤动。1998年9月，他创办了私营公司Syntheon，专注经营用于胃肠病和血管病市场的微创医疗器械。2002年10月至2006年3月，他是介入性心脏病上市公司Novoste Corporation的总裁、首席执行官、董事。1998年12月至2002年10月，他是血管闭合公司Sutura的董事。1996年7月至1998年1月，他担任电气生理学公司Biosense的总裁、首席执行官、董事。1984年4月至1996年7月，他受聘于心脏病学公司Cordis Corporation，当时是个上市公司，并曾担任总裁、首席财务官。
Alfred J. Novak has served as a member of our board of directors since May 2017. Mr. Novak has served on the board of LivaNova PLC, a global medical device company since October 2015. From 2007 until October 2015 Mr. Novak served on the board of Cyberonics, until its merger with Sorin S.p.a. to form LivaNova. From April 2014 until March 2015 Mr. Novak served as President and Chief Executive Officer of Syntheon Cardiology, LLC, an early-stage company developing a percutaneous prosthetic aortic heart valve. From September 1999 until January 2014 he served on the board of directors of OrbusNeich Medical Technology Company, Ltd., a privately held interventional cardiology company, and he was Chairman and Chief Executive Officer from 2010 until October 2013. From 2002 until 2006 Mr. Novak was the President, Chief Executive Officer and a director of Novoste Corporation, a publicly held interventional cardiology company. From 1998 until 2002 he was a founder of Syntheon, LLC, a privately held company that focused on minimally invasive medical devices for the gastroenterology and vascular markets. Mr. Novak was a Director, Chief Executive Officer and Chief Financial Officer of public and private companies. He received an M.B.A. from the Wharton School, University of Pennsylvania, and a B.S. from the United States Merchant Marine Academy. - Alfred J. Novak，2007年1月被任命为本公司董事会成员。1999年9月起，他是OrbusNeich Medical Technology Company的董事会成员，这是一个介入性心脏病方面的私营公司，他在2010年1月当选为董事长兼首席执行官。之前，他曾担任ProRhythm的董事长，该公司致力于通过采用超声波技术治疗心房颤动。1998年9月，他创办了私营公司Syntheon，专注经营用于胃肠病和血管病市场的微创医疗器械。2002年10月至2006年3月，他是介入性心脏病上市公司Novoste Corporation的总裁、首席执行官、董事。1998年12月至2002年10月，他是血管闭合公司Sutura的董事。1996年7月至1998年1月，他担任电气生理学公司Biosense的总裁、首席执行官、董事。1984年4月至1996年7月，他受聘于心脏病学公司Cordis Corporation，当时是个上市公司，并曾担任总裁、首席财务官。
- Alfred J. Novak has served as a member of our board of directors since May 2017. Mr. Novak has served on the board of LivaNova PLC, a global medical device company since October 2015. From 2007 until October 2015 Mr. Novak served on the board of Cyberonics, until its merger with Sorin S.p.a. to form LivaNova. From April 2014 until March 2015 Mr. Novak served as President and Chief Executive Officer of Syntheon Cardiology, LLC, an early-stage company developing a percutaneous prosthetic aortic heart valve. From September 1999 until January 2014 he served on the board of directors of OrbusNeich Medical Technology Company, Ltd., a privately held interventional cardiology company, and he was Chairman and Chief Executive Officer from 2010 until October 2013. From 2002 until 2006 Mr. Novak was the President, Chief Executive Officer and a director of Novoste Corporation, a publicly held interventional cardiology company. From 1998 until 2002 he was a founder of Syntheon, LLC, a privately held company that focused on minimally invasive medical devices for the gastroenterology and vascular markets. Mr. Novak was a Director, Chief Executive Officer and Chief Financial Officer of public and private companies. He received an M.B.A. from the Wharton School, University of Pennsylvania, and a B.S. from the United States Merchant Marine Academy.
- Arthur L. Rosenthal
-
Arthur L. Rosenthal，2007年1月被任命为本公司董事会成员。自2012年4月以来，他是gEyeCue Medical Systems的联合创始人、首席执行官，这是总部在爱尔兰高威的一个开发阶段公司，从事智能活体检视系统的开发；自2011年6月起，他是一名医疗技术顾问。从2009年6月至2011年6月，他担任 Cappella的总裁、首席执行官，这是专注于为冠状动脉疾病的开发阶段公司，他继续担任该公司执行副董事长，直到2012年7月。2002年1月起，他担任Labcoat的董事长；2005年1月起，担任首席执行官，直到2008年12月该公司被 Boston Scientific Corporation 收购。从1994年1月至2000年5月，他是Boston Scientific的高级副总裁、企业高管、首席开发官；从2000年5月直到他2005年1月退休，他担任高级副总裁、首席科学官，执行委员会成员。2000-2010，他是Renovo的非执行董事；2006-2010，他担任薪酬委员会主席，这是位于英国的一家制药公司，在2006年上市交易。2009年7月，他任职于 Interface Biologics的董事会，担任非执行董事，这是一家位于多伦多的发展阶段公司，专注于药物输送装置相关业务。 2011年4月，他被选任为Interface Biologics的董事长，并加入Arch Therapeutics（ 美国场外交易代码：ARTH）的董事会，这是位于马萨诸塞州纳提克的生命科学公司，从事停止或控制出血的液休聚合物的开发。从2011年6月至2013年5月，他担任 Tornado Medical Systems 的非执行董事，该公司总部在多伦多，是从事医学成像和光谱业务的早期阶段公司。目前，他是波士顿大学工程学院生物医学工程的实践教授，也是爱尔兰生命科学初创公司的美国大使。
Arthur L. Rosenthal was appointed to to LivaNova’s Board of Directors as a non-executive director in October 2015. Since, July 2009 Dr. Rosenthal has served as a non-executive director on the board of Interface Biologics, Inc., a Toronto-based development-stage company focused on drug delivery devices. Previously, Dr. Rosenthal served on the board of directors of Cyberonics Inc. from January 2007 to October 2015. Since December 2011 Dr. Rosenthal has also served as Chief Executive Officer of EyeCue, Ltd., which he co-founded, a development-stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening. From June 2011 until July 2012 he served as Executive Vice Chairman of Cappella Medical Devices Ltd. now ArraVasc Ltd., a development-stage company focused on novel device solutions for coronary artery disease. From June 2009 until June 2011 he served as President and Chief Executive Officer of Cappella, Inc. Dr. Rosenthal served as Chairman, from January 2002 and Chief Executive Officer, commencing in January 2005 of Labcoat, Ltd. until its acquisition by Boston Scientific in December 2008. From January 1994 to May 2000 he was a Senior Vice President, Corporate Officer, and Chief Development Officer of Boston Scientific Corporation, and from May 2000 until his retirement in January 2005 he was a Senior Vice President, Chief Scientific Officer, and Executive Committee Member of Boston Scientific. From January 2010 to June 2015 Dr. Rosenthal also served as Professor of Practice in the Biomedical Engineering Department at Boston University. Dr. Rosenthal served as a non-executive director, from 2000 until 2010 and as Chairman of the Remuneration Committee, from 2006 through 2009 of Renovo, Ltd., a U.K.-based pharmaceutical company that became publicly traded in 2006. In April 2011 he was elected Chairman at Interface Biologics, Inc. From June 2011 until May 2015 he served on the board of directors of Arch Therapeutics, Inc., a life science company based in Natick, MA developing liquid polymers to stop or control bleeding. Dr. Rosenthal earned a Ph.D. in Biochemistry from the University of Massachusetts and a Bachelor Degree in Bacteriology from the University of Connecticut. - Arthur L. Rosenthal，2007年1月被任命为本公司董事会成员。自2012年4月以来，他是gEyeCue Medical Systems的联合创始人、首席执行官，这是总部在爱尔兰高威的一个开发阶段公司，从事智能活体检视系统的开发；自2011年6月起，他是一名医疗技术顾问。从2009年6月至2011年6月，他担任 Cappella的总裁、首席执行官，这是专注于为冠状动脉疾病的开发阶段公司，他继续担任该公司执行副董事长，直到2012年7月。2002年1月起，他担任Labcoat的董事长；2005年1月起，担任首席执行官，直到2008年12月该公司被 Boston Scientific Corporation 收购。从1994年1月至2000年5月，他是Boston Scientific的高级副总裁、企业高管、首席开发官；从2000年5月直到他2005年1月退休，他担任高级副总裁、首席科学官，执行委员会成员。2000-2010，他是Renovo的非执行董事；2006-2010，他担任薪酬委员会主席，这是位于英国的一家制药公司，在2006年上市交易。2009年7月，他任职于 Interface Biologics的董事会，担任非执行董事，这是一家位于多伦多的发展阶段公司，专注于药物输送装置相关业务。 2011年4月，他被选任为Interface Biologics的董事长，并加入Arch Therapeutics（ 美国场外交易代码：ARTH）的董事会，这是位于马萨诸塞州纳提克的生命科学公司，从事停止或控制出血的液休聚合物的开发。从2011年6月至2013年5月，他担任 Tornado Medical Systems 的非执行董事，该公司总部在多伦多，是从事医学成像和光谱业务的早期阶段公司。目前，他是波士顿大学工程学院生物医学工程的实践教授，也是爱尔兰生命科学初创公司的美国大使。
- Arthur L. Rosenthal was appointed to to LivaNova’s Board of Directors as a non-executive director in October 2015. Since, July 2009 Dr. Rosenthal has served as a non-executive director on the board of Interface Biologics, Inc., a Toronto-based development-stage company focused on drug delivery devices. Previously, Dr. Rosenthal served on the board of directors of Cyberonics Inc. from January 2007 to October 2015. Since December 2011 Dr. Rosenthal has also served as Chief Executive Officer of EyeCue, Ltd., which he co-founded, a development-stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening. From June 2011 until July 2012 he served as Executive Vice Chairman of Cappella Medical Devices Ltd. now ArraVasc Ltd., a development-stage company focused on novel device solutions for coronary artery disease. From June 2009 until June 2011 he served as President and Chief Executive Officer of Cappella, Inc. Dr. Rosenthal served as Chairman, from January 2002 and Chief Executive Officer, commencing in January 2005 of Labcoat, Ltd. until its acquisition by Boston Scientific in December 2008. From January 1994 to May 2000 he was a Senior Vice President, Corporate Officer, and Chief Development Officer of Boston Scientific Corporation, and from May 2000 until his retirement in January 2005 he was a Senior Vice President, Chief Scientific Officer, and Executive Committee Member of Boston Scientific. From January 2010 to June 2015 Dr. Rosenthal also served as Professor of Practice in the Biomedical Engineering Department at Boston University. Dr. Rosenthal served as a non-executive director, from 2000 until 2010 and as Chairman of the Remuneration Committee, from 2006 through 2009 of Renovo, Ltd., a U.K.-based pharmaceutical company that became publicly traded in 2006. In April 2011 he was elected Chairman at Interface Biologics, Inc. From June 2011 until May 2015 he served on the board of directors of Arch Therapeutics, Inc., a life science company based in Natick, MA developing liquid polymers to stop or control bleeding. Dr. Rosenthal earned a Ph.D. in Biochemistry from the University of Massachusetts and a Bachelor Degree in Bacteriology from the University of Connecticut.
- Jon T. Tremmel
-
Jon T. Tremmel，2010年被选任为本公司董事。2007年4月从Medtronic退休后，他成为一名业务顾问；从2003年3月起，他担任该公司神经科部门总裁；2001年5月至2003年3月，担任生理控制部门总裁；1992-2001，他担任快速性心律失常管理与介入血管部门的总裁。自1978年加入Medtronic到1992年，他担任多个愈益重要的职务。目前，他是以下公司的董事和薪酬委员会成员：EnteroMedics，从事开发治疗肥胖症的神经刺激装置的上市公司；Flowonix Medical Incorporated，从事开发治疗慢性疼痛的植入泵的私营公司。
Jon T. Tremmel,has served as one of our directors since January 2009. Mr. Tremmel has been retired and acting as an independent consultant since 2007. Over the course of his career at Medtronic, Inc., Mr. Tremmel served in a variety of senior management positions, including President of the Neurological Division from 2003 to 2007 President of the Physio Control Division, President of the Tachyarrhythmia Management Division and President of the Interventional Vascular Division. Mr. Tremmel currently serves on the board of Cyberonics, Inc., a publicly-held company that designs, develops and markets implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders and, Nuvectra Corp, a publically-held neuromodulation medical device company focused on the development of neurostimulation technology to treat various disorders of the nervous systems. - Jon T. Tremmel，2010年被选任为本公司董事。2007年4月从Medtronic退休后，他成为一名业务顾问；从2003年3月起，他担任该公司神经科部门总裁；2001年5月至2003年3月，担任生理控制部门总裁；1992-2001，他担任快速性心律失常管理与介入血管部门的总裁。自1978年加入Medtronic到1992年，他担任多个愈益重要的职务。目前，他是以下公司的董事和薪酬委员会成员：EnteroMedics，从事开发治疗肥胖症的神经刺激装置的上市公司；Flowonix Medical Incorporated，从事开发治疗慢性疼痛的植入泵的私营公司。
- Jon T. Tremmel,has served as one of our directors since January 2009. Mr. Tremmel has been retired and acting as an independent consultant since 2007. Over the course of his career at Medtronic, Inc., Mr. Tremmel served in a variety of senior management positions, including President of the Neurological Division from 2003 to 2007 President of the Physio Control Division, President of the Tachyarrhythmia Management Division and President of the Interventional Vascular Division. Mr. Tremmel currently serves on the board of Cyberonics, Inc., a publicly-held company that designs, develops and markets implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders and, Nuvectra Corp, a publically-held neuromodulation medical device company focused on the development of neurostimulation technology to treat various disorders of the nervous systems.
高管简历
中英对照 | 中文 | 英文- Rohan H. Hoare
Rohan H. Hoare，Hoare博士于2013年9月加入我司，担任战略规划部高级副总裁。他于2014年4月晋升为高级副总裁与首席运营官。从2012年12月到2013年9月，Hoare博士是一位独立的医疗技术咨询师。从2004年到2012年12月，他受聘于圣犹达医疗公司（St. Jude Medical, Inc.）的神经调节部门。在这之前，受聘于Advanced Neuromodulation Systems, Inc.，他在该公司先后担任过一系列职责递增的职位。这些职位包括从2012年9月到2012年12月的高级顾问，从2011年8月到2012年9月的总裁，从2008年到2012年的研发部副总裁，从2005年到2008年的战略与新兴疗法部的副总裁，以及从2004年到2005年的战略部副总裁。从1993年到2003年，Hoare博士在麦肯锡公司（McKinsey & Company）任职。他在澳大利亚墨尔本的莫纳什大学（Monash University）获得物理学理学学士学位，并被授予“理学院学者”荣誉称号。他作为富布莱特学者继续在哈佛大学（Harvard University）就读，他在该校获得文学硕士学位与物理学博士学位。
Rohan H. Hoare.Dr. Hoare joined us in September 2013 as Senior Vice President, Strategic Planning. In April 2014 he was promoted to Senior Vice President & Chief Operating Officer. From December 2012 to September 2013 Dr. Hoare was an independent medical technology consultant. From 2004 to December 2012 he was employed in the Neuromodulation Division of St. Jude Medical, Inc. formerly, Advanced Neuromodulation Systems, Inc., where he held a series of positions of successively greater responsibility. These positions included Senior Advisor (September 2012 to December 2012), President (August 2011 to September 2012), Vice President, Research & Development (2008 to 2012), Vice President, Strategy & Emerging Therapies (2005 to 2008), and Vice President, Strategy (2004 to 2005). From 1993 to 2003 Dr. Hoare worked for McKinsey & Company. He received a Bachelor of Science in Physics and was awarded Faculty of Science Scholar honors at Monash University in Melbourne, Australia. He continued his studies at Harvard University as a Fulbright Scholar, where he received a Master of Arts and a Ph.D. in Physics.- Rohan H. Hoare，Hoare博士于2013年9月加入我司，担任战略规划部高级副总裁。他于2014年4月晋升为高级副总裁与首席运营官。从2012年12月到2013年9月，Hoare博士是一位独立的医疗技术咨询师。从2004年到2012年12月，他受聘于圣犹达医疗公司（St. Jude Medical, Inc.）的神经调节部门。在这之前，受聘于Advanced Neuromodulation Systems, Inc.，他在该公司先后担任过一系列职责递增的职位。这些职位包括从2012年9月到2012年12月的高级顾问，从2011年8月到2012年9月的总裁，从2008年到2012年的研发部副总裁，从2005年到2008年的战略与新兴疗法部的副总裁，以及从2004年到2005年的战略部副总裁。从1993年到2003年，Hoare博士在麦肯锡公司（McKinsey & Company）任职。他在澳大利亚墨尔本的莫纳什大学（Monash University）获得物理学理学学士学位，并被授予“理学院学者”荣誉称号。他作为富布莱特学者继续在哈佛大学（Harvard University）就读，他在该校获得文学硕士学位与物理学博士学位。
- Rohan H. Hoare.Dr. Hoare joined us in September 2013 as Senior Vice President, Strategic Planning. In April 2014 he was promoted to Senior Vice President & Chief Operating Officer. From December 2012 to September 2013 Dr. Hoare was an independent medical technology consultant. From 2004 to December 2012 he was employed in the Neuromodulation Division of St. Jude Medical, Inc. formerly, Advanced Neuromodulation Systems, Inc., where he held a series of positions of successively greater responsibility. These positions included Senior Advisor (September 2012 to December 2012), President (August 2011 to September 2012), Vice President, Research & Development (2008 to 2012), Vice President, Strategy & Emerging Therapies (2005 to 2008), and Vice President, Strategy (2004 to 2005). From 1993 to 2003 Dr. Hoare worked for McKinsey & Company. He received a Bachelor of Science in Physics and was awarded Faculty of Science Scholar honors at Monash University in Melbourne, Australia. He continued his studies at Harvard University as a Fulbright Scholar, where he received a Master of Arts and a Ph.D. in Physics.
- Daniel J. Moore
Daniel J. Moore，2007年5月被任命为本公司董事，与此同时，他被本公司董事会任命为总裁兼首席执行官。加入本公司前，他任职于 Boston Scientific Corporation（Boston Scientific）， 这是一个多元化的微创医疗产品制造公司；他从1989年以来，在该公司的美国和欧洲业务部门担任过多个销售、营销和高级管理的职务。他在Boston Scientific 的最后职位是国际分销商管理总裁。担任该职之前，他是 Boston Scientific第4大业务部门Inter-Continental的总裁，该部门在全球有1000多名员工，营业额超过7亿美元。他也曾在Boston Scientific 的美国国内和国际性部门担任过高级管理职位。他目前担任美国癫痫基金会、德克萨斯癫痫基金会（前任会长）、德克萨斯州-休斯敦癫痫基金会（前任主席）的董事，也是医疗器械制造商协会的董事长，还是以下机构的董事或咨询委员会成员： BioHouston、Medical Device Innovation Consortium、Weldon School of Biomedical Engineering at Purdue University。他还是两家私营公司的董事：TriVascular，是一家医疗技术公司，为主动脉腔内修复提供器械的解决方案；BrainScope，专注于创伤性脑板伤害的医疗技术公司。由于他在担任Boston Scientific的主管人员时，还是阿根廷分公司的董事，他成为了2011年5月在布宜诺斯艾利斯联邦刑事和惩教事务法院4号法庭提起的刑事诉讼的几名被告之一。该诉讼涉及到与2006年心脏支架销售的公开招标有关的涉嫌欺诈行为。他否认了对指控的欺诈行为的任何知情或罪责，并敦促撤消指控。
Daniel J. Moore was appointed as Chairman of LivaNova's Board of Directors in September 2015. In addition to our Board, Mr.. Moore currently serves on the board of directors of GI Dynamics, Inc. Chairman, BrainScope Company, Inc. (Chairman), a company focused on traumatic brain injury, the BioHouston Executive Committee, Weldon School of Biomedical Engineering Advisory Board, and the Epilepsy Foundation of America. Previously, beginning in 2007 Mr.. Moore was a member of the Board and served as Chief Executive Officer of Cyberonics. Mr.. Moore joined Cyberonics from Boston Scientific, where, since 1989 he held positions in sales, marketing and senior management in the U.S. and in Europe. His last position at Boston Scientific was President, International Distributor Management. Prior to that role, he held the position of President, Inter-Continental, the fourth largest business unit of Boston Scientific, with more than 1000 global employees and revenues exceeding $700 million. Past board positions include: Topera, Inc. (acquired by Abbott Laboratories), TriVascular Technologies, Inc. (acquired by Endologix, Inc.), the Medical Device Manufacturers Association (past-Chairman), Smiling Kids, Inc., the Epilepsy Foundation of Texas (past-Chairman) and the Epilepsy Foundation of Texas-Houston (past President). Mr.. Moore earned an Executive MBA from Boston University and a Bachelor of Arts in Economics from Harvard College.- Daniel J. Moore，2007年5月被任命为本公司董事，与此同时，他被本公司董事会任命为总裁兼首席执行官。加入本公司前，他任职于 Boston Scientific Corporation（Boston Scientific）， 这是一个多元化的微创医疗产品制造公司；他从1989年以来，在该公司的美国和欧洲业务部门担任过多个销售、营销和高级管理的职务。他在Boston Scientific 的最后职位是国际分销商管理总裁。担任该职之前，他是 Boston Scientific第4大业务部门Inter-Continental的总裁，该部门在全球有1000多名员工，营业额超过7亿美元。他也曾在Boston Scientific 的美国国内和国际性部门担任过高级管理职位。他目前担任美国癫痫基金会、德克萨斯癫痫基金会（前任会长）、德克萨斯州-休斯敦癫痫基金会（前任主席）的董事，也是医疗器械制造商协会的董事长，还是以下机构的董事或咨询委员会成员： BioHouston、Medical Device Innovation Consortium、Weldon School of Biomedical Engineering at Purdue University。他还是两家私营公司的董事：TriVascular，是一家医疗技术公司，为主动脉腔内修复提供器械的解决方案；BrainScope，专注于创伤性脑板伤害的医疗技术公司。由于他在担任Boston Scientific的主管人员时，还是阿根廷分公司的董事，他成为了2011年5月在布宜诺斯艾利斯联邦刑事和惩教事务法院4号法庭提起的刑事诉讼的几名被告之一。该诉讼涉及到与2006年心脏支架销售的公开招标有关的涉嫌欺诈行为。他否认了对指控的欺诈行为的任何知情或罪责，并敦促撤消指控。
- Daniel J. Moore was appointed as Chairman of LivaNova's Board of Directors in September 2015. In addition to our Board, Mr.. Moore currently serves on the board of directors of GI Dynamics, Inc. Chairman, BrainScope Company, Inc. (Chairman), a company focused on traumatic brain injury, the BioHouston Executive Committee, Weldon School of Biomedical Engineering Advisory Board, and the Epilepsy Foundation of America. Previously, beginning in 2007 Mr.. Moore was a member of the Board and served as Chief Executive Officer of Cyberonics. Mr.. Moore joined Cyberonics from Boston Scientific, where, since 1989 he held positions in sales, marketing and senior management in the U.S. and in Europe. His last position at Boston Scientific was President, International Distributor Management. Prior to that role, he held the position of President, Inter-Continental, the fourth largest business unit of Boston Scientific, with more than 1000 global employees and revenues exceeding $700 million. Past board positions include: Topera, Inc. (acquired by Abbott Laboratories), TriVascular Technologies, Inc. (acquired by Endologix, Inc.), the Medical Device Manufacturers Association (past-Chairman), Smiling Kids, Inc., the Epilepsy Foundation of Texas (past-Chairman) and the Epilepsy Foundation of Texas-Houston (past President). Mr.. Moore earned an Executive MBA from Boston University and a Bachelor of Arts in Economics from Harvard College.
- Gregory H. Browne
Gregory H. Browne，2007年7月加入本公司，担任财务副总裁、首席财务官。2011年4月，他晋升为高级财务副总裁、首席财务官。他曾在一些医疗保健上市公司中担任首席执行官和首席财务官。2002年5月至2006年6月，他担任Amedisys的首席财务官，这是一家营收超过6亿美元的家庭护理公司，在此期间，该公司的营收、利润和市值获得大幅增长。2006年6月至2006年11月，他从事私人投资；2006年11月至2007年7月，他是行政服务公司Tatum的合伙人。2010年起，他担任WCS Corporation的董事、薪酬委员会成员，这是专注于伤害护理解决方案的私营公司。1996年，他创办了人力资源服务外包公司PeopleWorks，并担任总裁直到2001年3月，担任董事直到2001年10月。2001年11月，PeopleWorks根据美国破产法第11章申请破产重组；2002年申请转变为美国破产法第7章，该公司被清算。1992年1月至1995年7月，他担任精神疾病服务公司Ramsay Healthcare的首席执行官；1989-1991，担任健康保养机构Ramsay-HMO的首席执行官。
Gregory H. Browne,Mr. Browne joined us in July 2007 as Vice President, Finance & Chief Financial Officer "CFO". In April 2011 he was promoted to Senior Vice President, Finance & CFO. Mr. Browne has served as both CEO and CFO for several publicly traded healthcare companies. From May 2002 to June 2006 he was CFO at Amedisys, Inc., a home nursing company with revenues in excess of $600 million, during a period of substantial growth in revenue, profitability and market capitalization. From June 2006 to November 2006 Mr. Browne was a private investor, and from November 2006 to July 2007 he was a partner with Tatum, LLC, an executive services company. He was the founder in 1996 and served as President until March 2001 and a director until October 2001 of PeopleWorks, Inc., a human resource outsourcing company. From January 1992 to July 1995 he served as CEO for Ramsay Healthcare Inc., a provider of psychiatric services, and from 1989 to 1991 as CEO for Ramsay-HMO, Inc., a health maintenance organization. Since 2010 Mr. Browne has served as a director and member of the Compensation Committee of WCS Corporation, LLC, a privately held company focused on wound care solutions.- Gregory H. Browne，2007年7月加入本公司，担任财务副总裁、首席财务官。2011年4月，他晋升为高级财务副总裁、首席财务官。他曾在一些医疗保健上市公司中担任首席执行官和首席财务官。2002年5月至2006年6月，他担任Amedisys的首席财务官，这是一家营收超过6亿美元的家庭护理公司，在此期间，该公司的营收、利润和市值获得大幅增长。2006年6月至2006年11月，他从事私人投资；2006年11月至2007年7月，他是行政服务公司Tatum的合伙人。2010年起，他担任WCS Corporation的董事、薪酬委员会成员，这是专注于伤害护理解决方案的私营公司。1996年，他创办了人力资源服务外包公司PeopleWorks，并担任总裁直到2001年3月，担任董事直到2001年10月。2001年11月，PeopleWorks根据美国破产法第11章申请破产重组；2002年申请转变为美国破产法第7章，该公司被清算。1992年1月至1995年7月，他担任精神疾病服务公司Ramsay Healthcare的首席执行官；1989-1991，担任健康保养机构Ramsay-HMO的首席执行官。
- Gregory H. Browne,Mr. Browne joined us in July 2007 as Vice President, Finance & Chief Financial Officer "CFO". In April 2011 he was promoted to Senior Vice President, Finance & CFO. Mr. Browne has served as both CEO and CFO for several publicly traded healthcare companies. From May 2002 to June 2006 he was CFO at Amedisys, Inc., a home nursing company with revenues in excess of $600 million, during a period of substantial growth in revenue, profitability and market capitalization. From June 2006 to November 2006 Mr. Browne was a private investor, and from November 2006 to July 2007 he was a partner with Tatum, LLC, an executive services company. He was the founder in 1996 and served as President until March 2001 and a director until October 2001 of PeopleWorks, Inc., a human resource outsourcing company. From January 1992 to July 1995 he served as CEO for Ramsay Healthcare Inc., a provider of psychiatric services, and from 1989 to 1991 as CEO for Ramsay-HMO, Inc., a health maintenance organization. Since 2010 Mr. Browne has served as a director and member of the Compensation Committee of WCS Corporation, LLC, a privately held company focused on wound care solutions.
- David S. Wise
David S. Wise，2003年9月加入本公司，担任副总裁、法律总顾问。2003年11月，他被任命为本公司秘书。2009年6月，他负责人力资源部；2011年4月，他晋升为高级副总裁、行政总监、秘书，负责人力资源、信息技术、法律与政府事务。1994-2003，他在Centerpulse USA（原Sulzer Medica）担任过多个愈益重要的职务，该公司当时是一个多元化的全球性医疗器械公司，他最后的职务是部门副总裁兼法律总顾问。加入Centerpulse之前，他从事了12年的私人执业，主要是在知识产权和商业立法方面。目前，他是德克萨斯癫痫基金会的董事，也是德克萨斯-休斯敦癫痫基金会的董事及秘书。
David S. Wise has served as the Company’s Chief Administrative Officer since February 2017 with responsibility for Human Resources, Information Technology and Legal. He served as LivaNova’s Senior Vice President, Human Resources and Information Technology from October 2015 to February 2017. He has been an executive officer of LivaNova since October 2015. Previously, starting in April 2011 Mr.. Wise served as Senior Vice President and Chief Administrative Officer, as well as Secretary, of Cyberonics Inc., with responsibility for Human Resources, Information Technology, Legal and Government Affairs. From June 2009 to 2011 Mr.. Wise was Vice President, General Counsel and Secretary, as well as Vice President, Human Resources for Cyberonics, and earlier, from 2003 Mr.. Wise also served in the roles of Vice President, General Counsel and Secretary of Cyberonics. From 1994 to 2003 Mr.. Wise was employed in positions of increasing responsibility at Centerpulse USA, Inc. formerly Sulzer Medica, at the time a diverse global medical devices company, where he eventually served as Group Vice President and General Counsel. Prior to Centerpulse, he spent 12 years in private legal practice, focused on intellectual property and commercial litigation. Mr.. Wise holds a Bachelor of Science in Electrical Engineering from Rice University and a Juris Doctor cum laude from Duquesne University School of Law. He is a Registered Patent Attorney and is licensed as an attorney by the State Bar of Texas.- David S. Wise，2003年9月加入本公司，担任副总裁、法律总顾问。2003年11月，他被任命为本公司秘书。2009年6月，他负责人力资源部；2011年4月，他晋升为高级副总裁、行政总监、秘书，负责人力资源、信息技术、法律与政府事务。1994-2003，他在Centerpulse USA（原Sulzer Medica）担任过多个愈益重要的职务，该公司当时是一个多元化的全球性医疗器械公司，他最后的职务是部门副总裁兼法律总顾问。加入Centerpulse之前，他从事了12年的私人执业，主要是在知识产权和商业立法方面。目前，他是德克萨斯癫痫基金会的董事，也是德克萨斯-休斯敦癫痫基金会的董事及秘书。
- David S. Wise has served as the Company’s Chief Administrative Officer since February 2017 with responsibility for Human Resources, Information Technology and Legal. He served as LivaNova’s Senior Vice President, Human Resources and Information Technology from October 2015 to February 2017. He has been an executive officer of LivaNova since October 2015. Previously, starting in April 2011 Mr.. Wise served as Senior Vice President and Chief Administrative Officer, as well as Secretary, of Cyberonics Inc., with responsibility for Human Resources, Information Technology, Legal and Government Affairs. From June 2009 to 2011 Mr.. Wise was Vice President, General Counsel and Secretary, as well as Vice President, Human Resources for Cyberonics, and earlier, from 2003 Mr.. Wise also served in the roles of Vice President, General Counsel and Secretary of Cyberonics. From 1994 to 2003 Mr.. Wise was employed in positions of increasing responsibility at Centerpulse USA, Inc. formerly Sulzer Medica, at the time a diverse global medical devices company, where he eventually served as Group Vice President and General Counsel. Prior to Centerpulse, he spent 12 years in private legal practice, focused on intellectual property and commercial litigation. Mr.. Wise holds a Bachelor of Science in Electrical Engineering from Rice University and a Juris Doctor cum laude from Duquesne University School of Law. He is a Registered Patent Attorney and is licensed as an attorney by the State Bar of Texas.
- Darren W. Alch
Darren W. Alch，2005年8月加入本公司，担任合规官员、法律总顾问助理，当时他还担任隐私官。2010年12月，他被任命为助理企业秘书。2011年4月，他被任命为副总裁、企业法律顾问、合规官、助理秘书；2013年4月，他被任命担任现在的职务，副总裁、法律总顾问、助理秘书。加入Cyberonics之前，他是全国性的律师事务所Jenkens & Gilchrist卫生法规部门的股东，他于1996年加入该公司。任职于Jenkens & Gilchrist之前，他曾在制药公司辉瑞担任销售和营销的职务。他毕业于美国西点军校，并曾在美国陆军队服役，担任一名野战炮兵军官。
Darren W. Alch,Mr. Alch joined us in August 2005 as Compliance Officer and Assistant General Counsel. He also assumed the role of Privacy Officer at that time. He was appointed Assistant Corporate Secretary in December 2010. In April 2011 he was appointed to the position of Vice President, Corporate Counsel & Compliance Officer and Assistant Secretary, and in April 2013 he was appointed to his current position as Vice President, General Counsel and Assistant Secretary. Before joining Cyberonics, he was a shareholder in the health law group of the national law firm of Jenkens & Gilchrist, P.C., which he joined in 1996. Prior to Jenkens & Gilchrist, he worked for pharmaceutical manufacturer Pfizer, Inc. in a sales and marketing capacity. Mr. Alch is a graduate of the U.S. Military Academy at West Point, and served on active duty in the U.S. Army as a field artillery officer.- Darren W. Alch，2005年8月加入本公司，担任合规官员、法律总顾问助理，当时他还担任隐私官。2010年12月，他被任命为助理企业秘书。2011年4月，他被任命为副总裁、企业法律顾问、合规官、助理秘书；2013年4月，他被任命担任现在的职务，副总裁、法律总顾问、助理秘书。加入Cyberonics之前，他是全国性的律师事务所Jenkens & Gilchrist卫生法规部门的股东，他于1996年加入该公司。任职于Jenkens & Gilchrist之前，他曾在制药公司辉瑞担任销售和营销的职务。他毕业于美国西点军校，并曾在美国陆军队服役，担任一名野战炮兵军官。
- Darren W. Alch,Mr. Alch joined us in August 2005 as Compliance Officer and Assistant General Counsel. He also assumed the role of Privacy Officer at that time. He was appointed Assistant Corporate Secretary in December 2010. In April 2011 he was appointed to the position of Vice President, Corporate Counsel & Compliance Officer and Assistant Secretary, and in April 2013 he was appointed to his current position as Vice President, General Counsel and Assistant Secretary. Before joining Cyberonics, he was a shareholder in the health law group of the national law firm of Jenkens & Gilchrist, P.C., which he joined in 1996. Prior to Jenkens & Gilchrist, he worked for pharmaceutical manufacturer Pfizer, Inc. in a sales and marketing capacity. Mr. Alch is a graduate of the U.S. Military Academy at West Point, and served on active duty in the U.S. Army as a field artillery officer.